Antibodies News and Research

RSS

AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

AbbVie today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders.

19 Mar 2015

Neurology Times features special coverage of MS in observance of MS Awareness Month

UBM Medica US announces that Neurology Times, a leading online community and information resource for neurologists and other healthcare providers, is featuring special coverage of multiple sclerosis in observance of MS Awareness Month.

19 Mar 2015

Austrian Centre of Industrial Biotechnology develops method to reduce production costs of valuable drugs

Imagine a loved relative suffering from cancer - and you could not afford a treatment because the drugs are too expensive. The Austrian Centre of Industrial Biotechnology (acib) developed a method with the power to reduce production costs of highly valued drugs significantly.

19 Mar 2015

Janssen Pharmaceutical to invest $10 million in global Dementia Discovery Fund

Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will invest $10 million in a new UK government-led global dementia discovery fund that will support innovative research to help find new ways to prevent and treat dementia and Alzheimer's disease.

17 Mar 2015

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Professor Raja Atreya from Medical Clinic 1 of the Erlangen University Hospital has won the 60,000€ Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers for 2015. With his innovative diagnostic method, physicians can predict the clinical response of an expensive treatment of Crohn's disease which is associated with potential side effects.

17 Mar 2015

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Inc. and Sorrento Therapeutics, Inc., announced today that they have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach.

16 Mar 2015

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Metastatic melanoma is the leading cause of skin cancer deaths in the United States; once melanoma has spread (metastasized), life expectancy for patients can be dramatically shortened.

13 Mar 2015

New immunotoxin found to be safe, effective in patients with B-cell malignancies

Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained.

13 Mar 2015

'Turbocharged' protein holds promise in hemophilia gene therapy

Using gene therapy to produce a mutant human protein with unusually high blood-clotting power, scientists have successfully treated dogs with the bleeding disorder hemophilia, without triggering an unwanted immune response.

13 Mar 2015

Researcher shares study results of periodontitis and RA at IADR General Session

Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Sheila Arvikar, Massachusetts General Hospital, Boston, USA, will present a study titled "Inflammation in the Mouth and Joints in Rheumatoid Arthritis."

13 Mar 2015

Non-invasive ultrasound technology can treat Alzheimer's disease, restore memory

Queensland scientists have found that non-invasive ultrasound technology can be used to treat Alzheimer's disease and restore memory.

13 Mar 2015

Study: New gene therapy safe, effective for patients with hemophilia B

A multi-year, ongoing study suggests that a new kind of gene therapy for hemophilia B could be safe and effective for human patients. Published in the journal Science Translational Medicine, the research showed that a reprogrammed retrovirus could successfully transfer new factor IX (clotting) genes into animals with hemophilia B to dramatically decrease spontaneous bleeding.

12 Mar 2015

Understanding strengths and weaknesses of hepatitis C viruses

Using a specially selected library of different hepatitis C viruses, a team of researchers led by Johns Hopkins scientists has identified tiny differences in the pathogens' outer shell proteins that underpin their resistance to antibodies.

12 Mar 2015

Wistar awarded grant to create Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium

The Jayne Koskinas Ted Giovanis Foundation awarded The Wistar Institute a $1.1 million grant to create The Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium at The Wistar Institute. The Consortium will support the highly synergistic, multidisciplinary research projects of three Wistar scientists dedicated to advancing breast cancer research.

12 Mar 2015

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Sigma-Aldrich Corporation today announced that SAFC Commercial, its custom manufacturing services business unit, has entered a commercial sales and service contract with leading biopharmaceutical company, BeiGene.

11 Mar 2015

Weak spots in ebola’s defenses: an interview with Dr. Andrew Ward

There are hundreds of other antibodies against Ebola that we are in the process of imaging using the electron microscope. We are looking for new sites of vulnerability as well as subtle differences in the way the known sites are attacked. In particular we are looking for antibodies that the virus is unlikely to escape from when it mutates.

11 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

Finding appears to support the hypothesis that Alzheimer's is an autoimmune disease

Brain levels of the lipid ceramide are high in Alzheimer's disease, and now scientists have found increased levels of an antibody to the lipid in their disease model.

10 Mar 2015

Narcolepsy bears trademarks of classic autoimmune disorder

Narcoleptics suffer from bouts of sleepiness and sleep attacks, which impair their ability to function in daily life. But the precise cause of narcolepsy has long eluded scientists, and the cure for the devastating neurological disorder afflicting an estimated three million people worldwide -- and one in 3,000 Americans -- remains at bay.

10 Mar 2015

Imperial scientists develop new test that uses human stem cells to predict side effects of drugs

Scientists at Imperial College London have developed a test that uses combinations of cells from a single donor's blood to predict whether a new drug will cause a severe immune reaction in humans.

10 Mar 2015

Antibodies News and Research

AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

Neurology Times features special coverage of MS in observance of MS Awareness Month

Austrian Centre of Industrial Biotechnology develops method to reduce production costs of valuable drugs

Janssen Pharmaceutical to invest $10 million in global Dementia Discovery Fund

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

New immunotoxin found to be safe, effective in patients with B-cell malignancies

'Turbocharged' protein holds promise in hemophilia gene therapy

Researcher shares study results of periodontitis and RA at IADR General Session

Non-invasive ultrasound technology can treat Alzheimer's disease, restore memory

Study: New gene therapy safe, effective for patients with hemophilia B

Understanding strengths and weaknesses of hepatitis C viruses

Wistar awarded grant to create Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Weak spots in ebola’s defenses: an interview with Dr. Andrew Ward

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Finding appears to support the hypothesis that Alzheimer's is an autoimmune disease

Narcolepsy bears trademarks of classic autoimmune disorder

Imperial scientists develop new test that uses human stem cells to predict side effects of drugs

Antibodies eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News